Tirzepatide has emerged as a groundbreaking therapy for type 2 diabetes, offering promising results. However, the cost of this innovative drug and its supply have become key Eli Lilly supplier concerns for patients and healthcare professionals. While tirzepatide has been cleared by regulatory agencies, its expensive nature presents a significant b